Monday, 26 Jun 2017

You are here

Above-Label Dosing and Noncompliance with Biologics in Psoriatic Arthritis

In this era of treat-to-target or remission targeted therapeutics, the options in managing nonresponders are many; often including off-label doses (i.e., dose escalations or reduction, increasing frequency; interrupted treatment). The use of above-label dosing, and its' effect on drug costs, has seldom been studied. 

Schwartzman and colleagues have studied biologic utilization in psoriatic arthritis (PsA), and the economic impact of increased doses, specifically looking at costs associated with above-label dosing and noncompliance with biologics in PsA.

Using MarketScan claims data they analyzed the first biologic claim with a 1-year follow-up period. The duration of use was stratified into three groups: <30, 30–179, and ≥180 days and defined above-label dosing as >10% of the labeled dose. They analyzed 4245 PsA patients treated with common biolgics (etanercept; n = 2342 ; adalimumab 1788, golimumab 115) between 2011 - 2013.

Above-label dosing for  <30 days was common and seen in 85% of adalimumab, 90.4% of etanercept, and 95.7% of golimumab patients. Longer term (≥180 days) was less common  (9.6% adalimumab, 4.1% etanercept, and 2.6% golimumab).

The mean number of days of on-label use ranged from 267 (adalimumab) to 295 (golimumab).

The mean number of days of above-label use was lowest with golimumab (12 days) and highest with adalimumab (35 days). Etanercept days of above-label use was 17  days.

Noncompliance could be inferred by no-use or below-label use days.  Below-label use was onlyreported for etanercept (4days) and adalimumab (1 day). No use was significantly higher for etanercept (71 days), compared to adalimumab (63 days), and golimumab (59 days).

All-cause total healthcare costs rose substantially with above-label use (p < 0.05).

These analyses suggest noncompliance with biologics is very common and that above-label use of anti-TNF biologics not only occurs, but is associated with significantly increased healthcare costs.

The clinical consequences or associations of these off-label dosing practices could not be studied in this claims dataset.

Dr. Schwartman collaborated with Novartis to perform these studies.

 

Disclosures: 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

IV Golimumab in Psoriatic Arthritis

Based on recent clinical trials, the makers of golimumab have petitioned the FDA for new indications in PsA and AS. Trials for PsA (GO-VIBRANT) and AS (GO-ALIVE) were presented at last weeks EULAR 2017 meeting in Madrid, Spain.

Tildrakizumab, an IL-23 Inhibitor, is Successful in Plaque Psoriasis

Therapeutic options for cutaneous psoriasis (and psoriatic arthritis as well) are rapidly expanding.  Lancet has published the impressive results of two phase III trials of tildrakizumab, a IgG1 antibody against interleukin 23 p19, in patients with active chronic plaque psoriasis.

Low Dose Treatment in Ankylosing Spondylitis Still Effective

About one-third of ankylosing spondylitis patients who cut their etanercept (Enbrel) dose in half maintained responses over 4 years, compared with two-thirds who stayed on standard therapy, researchers reported.

Ixekizumab Effective in TNF Failure Psoriatic Arthritis - SPIRIT-P2 Trial

Ixekizumab (Taltz) is currently approved for use in plaque psoriasis and is being developed for use in psoriatic arthritis (PsA). New results show IXE to be highly effective at skin and joint outcomes in PsA patients who have failed a TNF inhibitor (TNFi).

Adalimumab Effective in Pediatric Plaque Psoriasis

Adalimumab is currently FDA approved for use in adult psoriasis, pediatric Crohn's disease and polyarticular juvenile idiopathic arthritis.  The current Lancet trial assesses the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.